Towards host-directed therapies for tuberculosis.
Zumla A., Maeurer M., Host-Directed Therapies Network None., Chakaya J., Hoelscher M., Ntoumi F., Rustomjee R., Vilaplana C., Yeboah-Manu D., Rasolof V., Munderi P., Singh N., Aklillu E., Padayatchi N., Macete E., Kapata N., Mulenga M., Kibiki G., Mfinanga S., Nyirenda T., Maboko L., Garcia-Basteiro A., Rakotosamimanana N., Bates M., Mwaba P., Reither K., Gagneux S., Edwards S., Mfinanga E., Abdulla S., Cardona P-J., Russell JBW., Gant V., Noursadeghi M., Elkington P., Bonnet M., Menendez C., Dieye TN., Diarra B., Maiga A., Aseffa A., Parida S., Wejse C., Petersen E., Kaleebu P., Oliver M., Craig G., Corrah T., Tientcheu L., Antonio M., Rao M., McHugh TD., Sheikh A., Ippolito G., Ramjee G., Kaufmann SHE., Churchyard G., Steyn A., Grobusch M., Sanne I., Martinson N., Madansein R., Wilkinson RJ., Mayosi B., Schito M., Wallis RS.
The treatment of tuberculosis is based on combinations of drugs that directly target Mycobacterium tuberculosis. A new global initiative is now focusing on a complementary approach of developing adjunct host-directed therapies.